A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others ...
Dec 11, 2023
0
38
The viruses Kaposi sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) have been linked to several cancers. For the first time, UNC School of Medicine scientists have discovered that these viruses use a human ...
Feb 6, 2023
0
58
In a new study, the majority of individuals treated as children for Hodgkin lymphoma who are now in their 30s, showed signs of being an average of 7.7 years older biologically than their peers and placing them at risk for ...
Dec 12, 2022
0
5
A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one of the experimental mAbs ...
Oct 27, 2022
0
34
Treatment advances have improved the survival of individuals with Hodgkin lymphoma (HL)—a type of cancer that affects the lymphatic system—but therapies can increase patients' risk of developing heart problems. A recent ...
Jul 25, 2022
0
5
For patients with stage III or IV Hodgkin lymphoma, brentuximab vedotin is associated with a survival advantage, according to a study published online July 13 in the New England Journal of Medicine.
Jul 14, 2022
0
1
The method for assessing occupational pesticide exposure does not appear to influence risk estimates for prostate cancer, non-Hodgkin lymphoma, or Parkinson disease, according to a study published online April 13 in Occupational ...
Apr 18, 2022
0
5
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen ...
Dec 12, 2021
0
3
September is Leukemia and Lymphoma Awareness Month, which makes this a good time to learn about some of the most common types of these two diseases.
Sep 3, 2021
0
2
Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...
Apr 14, 2021
0
2
